SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet’s Disease…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Encouraging Results from Phase2a Trial of SGX945 in Behcet’s Disease On July 31, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced encouraging results from a Phase 2a clinical trial of SGX945 in Behcet’s disease (BD) in which the compound exhibited biological efficacy. These results are supportive of advancing the compound into a placebo-controlled Phase 2b trial,...